ICH E6(R3) Annex 2: GCP for Decentralised and RWD Trials
The final piece of the ICH E6(R3) Good Clinical Practice framework takes effect in the European Union on 15 January 2027.
The final piece of the ICH E6(R3) Good Clinical Practice framework takes effect in the European Union on 15 January 2027. Annex 2 explains how sponsors and investigators should apply GCP when trials move beyond the site, integrate routine care or draw on real-world data.
Where Annex 2 fits in the new GCP architecture
ICH E6(R3) is built in three parts: overarching principles, Annex 1 for interventional clinical trials, and Annex 2, which adds considerations for non-traditional designs. The regulatory members of the ICH Assembly endorsed Annex 2 at Step 4 on 3 June 2026. The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted it on 25 June 2026, with an EU effective date of 15 January 2027; the Principles and Annex 1 have applied in the EU since 23 July 2025. ICH published a consolidated version of all three parts in June 2026. Annex 2 is not a separate rulebook. It must be read alongside the Principles and Annex 1, and it states explicitly that it does not endorse any specific methodology. Its aim is practical: showing how a proportionate, risk-based approach to GCP applies to three families of trial "methodologies": Decentralised elements – activities conducted outside the investigator's location, such as home visits, local healthcare centres, mobile units, video calls and digital health technologies (DHTs) like apps, wearables and sensors. Pragmatic elements – aspects of usual clinical practice built into the design, for example eligibility criteria that reflect the real patient population, or streamlined data collection aligned with routine care. Real-world data (RWD) – health data generated outside the trial, from electronic health records, registries or claims databases, used for instance as endpoint data or as an external control.
What changes in practice for investigators
Remote informed consent. Consent may be obtained remotely where appropriate. The investigator must confirm the participant's identity – the guideline cites checking an official identity document during a video call as one option – and the verification method and privacy safeguards should be defined in advance. Where feasible, participants who prefer it should still be offered a paper-based or in-person process. Investigational product at home. The product may be dispensed or shipped to the participant or a designee, such as a caregiver or home nurse. When the sponsor organises direct-to-participant shipping, where local rules allow it, the investigator keeps responsibility for safe use, must be informed of receipt and any reported issues, and roles must be documented. Proportionate oversight. Depending on the activity and the criticality of the data, oversight can range from direct supervision to remote contact or the review of essential records. This includes healthcare professionals who perform trial-related tasks within their usual clinical practice. Safety signals from new sources. Information from home nursing, remote visits or DHTs must reach the investigator in a form that supports timely clinical decisions, not as an unmanageable stream of raw data.
Sponsor responsibilities: RWD, data governance and oversight
Annex 2 places most of the burden of data quality on the sponsor. The core expectations are: Fitness for purpose – RWD must be reliable (accuracy, completeness, provenance, traceability) and relevant (key data elements such as exposure, outcomes and covariates must be available). Access proportionate to criticality – when RWD support key efficacy or safety endpoints, sponsors may need access to source records to confirm that events occurred; for exploratory endpoints, system- and process-level assessments may be sufficient. Documented agreements with the hospitals, registries or insurers that own the data, including access for regulatory inspections. Consent or permission for data use in line with local requirements; for secondary use, approaches differ by region, from broad consent to ethics committee permission. Privacy and cybersecurity safeguards, especially when DHTs, remote collection or home deliveries expose personal information to service providers. Oversight of service providers, including when the sponsor arranges tasks that remain under the investigator's responsibility, such as home nursing. The guideline also encourages early engagement with patients, investigators and regulators whenever a design departs from the traditional site-based model.
What it means for trials in Morocco and the MENA region
ICH guidelines do not automatically bind countries outside the ICH regulatory membership, and Annex 2 itself makes remote consent, home management of investigational products and RWD use conditional on applicable regulatory requirements. In Morocco, biomedical research is governed by Law No. 28-13 on the protection of persons participating in biomedical research. Its implementing decree, No. 2.20.326, was amended by Decree No. 2.26.223 of 30 April 2026, published in the Bulletin officiel No. 7505 of 4 May 2026. For sponsors considering hybrid designs in the region, a few steps make the difference between a workable protocol and a costly amendment: Map each element – e-consent, home nursing, DHTs, direct-to-participant shipping, EHR extraction – against national law, ethics committee expectations and personal data protection rules at the feasibility stage. Describe and justify every methodology in the protocol, including safety data flows and consent modalities, as Annex 2 recommends. Assess local RWD sources candidly: variability of formats, missing data and consistency of coding systems. Plan participant support for digital literacy and connectivity gaps, with an alternative path for those who need it. For multinational sponsors, the real work lies in reconciling one global protocol with these local constraints, country by country.
Key takeaways
Annex 2 completes ICH E6(R3) and applies in the EU from 15 January 2027. It allows, but does not require, remote consent, home-based product management and RWD – always within local rules. Sponsors remain accountable for RWD fitness for purpose, data access and the oversight of every service provider.
Preparing for the next generation of trials
Annex 2 rewards sponsors who decide early which decentralised, pragmatic or RWD elements genuinely serve their trial question, and who verify local feasibility before the protocol is locked. MSHEALTH's clinical research team supports pharmaceutical and MedTech sponsors from protocol design through post-marketing surveillance, with ICH-GCP data management and regulatory reporting. To discuss a study in Morocco or the wider region, submit your RFP.
Sources
ICH – E6(R3) Guideline, Annex 2, final version adopted 3 June 2026 (copy hosted by PMDA): pmda.go.jp/files/000281183.pdf – accessed 16 November 2026 ICH – E6(R3) Final Consolidated Guideline (Principles, Annex 1 and Annex 2), 16 June 2026: database.ich.org – accessed 16 November 2026 European Medicines Agency – ICH E6 Good clinical practice, scientific guideline: ema.europa.eu – accessed 16 November 2026 Kingdom of Morocco, Ministry of Justice (Adala) – Law No. 28-13 on the protection of persons participating in biomedical research: adala.justice.gov.ma – accessed 16 November 2026 Kingdom of Morocco, Ministry of Justice (Adala) – Decree No. 2.20.326 as amended by Decree No. 2.26.223 (BO No. 7505, 4 May 2026), consolidated Arabic text: adala.justice.gov.ma – accessed 16 November 2026